Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
about
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Epidermal growth factor receptor in non-small cell lung cancerPharmGKB summary: very important pharmacogene information for the epidermal growth factor receptorKRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort studyMutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC)Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutationsGenetic alterations in lung adenocarcinoma with a micropapillary componentKRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literatureEGFR inhibition in non-small cell lung cancer: current evidence and future directionsMolecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyLow-frequency KRAS mutations are prevalent in lung adenocarcinomasRare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand.Selumetinib for the treatment of non-small cell lung cancer.The changing landscape of clinical trial and approval processes in China.Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion.Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.
P2860
Q27313799-A5D547E2-7EBE-4AF9-8AD8-5075D4F773FEQ28088636-CDDC8C39-8DF0-4791-8AB7-5E034324C98CQ28382921-F7211F28-B3E6-4142-9AC2-DA29210B590BQ33634165-49E0F8AB-7729-4890-9100-B2B4293FE5A6Q33648808-1582CD05-7683-4E6B-8D6B-911C795B0B08Q33690682-DF7E5C91-A55B-4F7A-B209-554CEB264743Q34235130-DB3C1FC5-62FA-4513-B442-C796A5CEC193Q34271752-3D956E63-3A78-46A0-A855-C744C2B053A1Q35749286-2C4363F2-44FB-4F73-992D-3E7571DF833FQ35824117-7788A20A-C64E-460F-B04C-2E22C7B435B6Q36216197-96160869-B21D-4354-A3DC-6DED0795F6F3Q36524569-2D20EFAE-1CBD-4471-9776-D63E51CCBAD2Q36946809-90FBFBBA-055B-4B74-AC78-F4343E635EDDQ37059866-41CDA265-9904-4A96-A058-5C1EA8D9B510Q37180302-99F5750F-7291-4EBA-A918-A6FAFAFCD8E5Q37347532-729C6342-49D0-4087-8B09-EED7E597B3B6Q37375834-B992AEDA-B7D5-4C02-B830-F45C4B73606BQ37404105-95001CA6-3637-41A5-B3D7-D028E9A85AC1Q38199478-8774E182-F04B-4CB3-B5D5-B8C799F50358Q38373208-BA80DEEF-C91B-40DC-AE5D-4F3421473CEFQ38663069-DFDD7852-1992-49BF-A304-82F0589B6D1AQ39134733-E61789DB-1549-4437-A068-FCCC300DFD2AQ39218108-DEA40195-8FF0-4D03-959A-7EBE116D58B4Q44070495-5B291D92-71B3-4B12-A580-A57F8ABB03EFQ54254003-687F5893-42A9-4937-A3CE-895BCB00CD49
P2860
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Impact of systematic EGFR and ...... ort (ERMETIC project--part 2).
@ast
Impact of systematic EGFR and ...... ort (ERMETIC project--part 2).
@en
Impact of systematic EGFR and ...... in a French prospective cohort
@nl
type
label
Impact of systematic EGFR and ...... ort (ERMETIC project--part 2).
@ast
Impact of systematic EGFR and ...... ort (ERMETIC project--part 2).
@en
Impact of systematic EGFR and ...... in a French prospective cohort
@nl
prefLabel
Impact of systematic EGFR and ...... ort (ERMETIC project--part 2).
@ast
Impact of systematic EGFR and ...... ort (ERMETIC project--part 2).
@en
Impact of systematic EGFR and ...... in a French prospective cohort
@nl
P2093
P50
P1476
Impact of systematic EGFR and ...... ort (ERMETIC project--part 2).
@en
P2093
Bruno Chetaille
Catherine Daniel
Elisabeth Longchampt
Elisabeth Quoix
Franck Morin
Guillaume Danton
Gérard Zalcman
Jacques Cadranel
Ludovic Lacroix
Martine Antoine
P304
P356
10.1097/JTO.0B013E318265B2B5
P50
P577
2012-10-01T00:00:00Z